Global Anti-Peptic Ulcer Drugs Market Size, Status and Forecast 2022

Anti-peptic Ulcre drug is one of various classes of drugs with different action mechanisms used to treat or ameliorate peptic ulcer or irritation of the gastrointestinal tract.
Global Anti-Peptic Ulcer Drugs key players include AstraZeneca, Ask-pharm, Takeda, Yangtze River Pharm, Shandong Luoxin, etc. Global top five players hold a share about 50%.
In terms of product, the segment includes Proton Pump Inhibitors (PPIs), Potassium-Competitive Acid Blockers (P-CAB), Antacids, H2 Antagonists, Ulcer Protective Drugs. And in terms of application, the application includes Gastritis, Gastric Ulcers, Duodenal Ulcers, Gastroesophageal Reflux Disease (GERD).

Market Analysis and Insights: Global Anti-Peptic Ulcer Drugs Market
The global Anti-Peptic Ulcer Drugs market size is projected to reach US$ 18530 million by 2027, from US$ 7692 million in 2020, at a CAGR of 13.4% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Anti-Peptic Ulcer Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Anti-Peptic Ulcer Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Anti-Peptic Ulcer Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Anti-Peptic Ulcer Drugs market.

Global Anti-Peptic Ulcer Drugs Scope and Market Size
Anti-Peptic Ulcer Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Anti-Peptic Ulcer Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Proton Pump Inhibitors (PPIs)
Potassium-Competitive Acid Blockers (P-CAB)
Antacids
H2 Antagonists
Ulcer Protective Drugs

Segment by Application
Gastritis
Gastric Ulcers
Duodenal Ulcers
Gastroesophageal Reflux Disease (GERD)

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
AstraZeneca
Ask-pharm
Takeda
Yangtze River Pharm
Shandong Luoxin
Huadong Medicine
Changzhou Siyao
Beijing Yuekang
Guangdong Dahua
Xian Janssen

Frequently Asked Questions